These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 27709117)

  • 21. Dyskinesias in patients with Parkinson's disease: effect of the leucine-rich repeat kinase 2 (LRRK2) G2019S mutation.
    Yahalom G; Kaplan N; Vituri A; Cohen OS; Inzelberg R; Kozlova E; Korczyn AD; Rosset S; Friedman E; Hassin-Baer S
    Parkinsonism Relat Disord; 2012 Nov; 18(9):1039-41. PubMed ID: 22703868
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Survival rates among Parkinson's disease patients who carry mutations in the LRRK2 and GBA genes.
    Thaler A; Kozlovski T; Gurevich T; Bar-Shira A; Gana-Weisz M; Orr-Urtreger A; Giladi N; Mirelman A
    Mov Disord; 2018 Oct; 33(10):1656-1660. PubMed ID: 30288804
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Analysis of the genetic variability in Parkinson's disease from Southern Spain.
    Bandrés-Ciga S; Mencacci NE; Durán R; Barrero FJ; Escamilla-Sevilla F; Morgan S; Hehir J; Vives F; Hardy J; Pittman AM
    Neurobiol Aging; 2016 Jan; 37():210.e1-210.e5. PubMed ID: 26518746
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mutations in glucocerebrosidase are a major genetic risk factor for Parkinson's disease and increase susceptibility to dementia in a Flanders-Belgian cohort.
    Crosiers D; Verstraeten A; Wauters E; Engelborghs S; Peeters K; Mattheijssens M; De Deyn PP; Theuns J; Van Broeckhoven C; Cras P
    Neurosci Lett; 2016 Aug; 629():160-164. PubMed ID: 27397011
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mutations in the glucocerebrosidase gene are common in patients with Parkinson's disease from Eastern Canada.
    Han F; Grimes DA; Li F; Wang T; Yu Z; Song N; Wu S; Racacho L; Bulman DE
    Int J Neurosci; 2016; 126(5):415-21. PubMed ID: 26000814
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of LRRK2 G2385R Variant on Subthalamic Deep Brain Stimulation Efficacy in Parkinson's Disease in a Han Chinese Population.
    Chen S; Liu H; Wu QQ; Xu SJ; Li WG; Chen T; Li C; Ma XY; Xu S; Liu YM
    Front Neurol; 2019; 10():1231. PubMed ID: 31824408
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A cognitive fMRI study in non-manifesting LRRK2 and GBA carriers.
    Bregman N; Thaler A; Mirelman A; Helmich RC; Gurevich T; Orr-Urtreger A; Marder K; Bressman S; Bloem BR; Giladi N;
    Brain Struct Funct; 2017 Apr; 222(3):1207-1218. PubMed ID: 27401793
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Genetic Identification in Early Onset Parkinsonism among Norwegian Patients.
    Gustavsson EK; Trinh J; McKenzie M; Bortnick S; Petersen MS; Farrer MJ; Aasly JO
    Mov Disord Clin Pract; 2017; 4(4):499-508. PubMed ID: 30363439
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reduced LRRK2 in association with retromer dysfunction in post-mortem brain tissue from LRRK2 mutation carriers.
    Zhao Y; Perera G; Takahashi-Fujigasaki J; Mash DC; Vonsattel JPG; Uchino A; Hasegawa K; Jeremy Nichols R; Holton JL; Murayama S; Dzamko N; Halliday GM
    Brain; 2018 Feb; 141(2):486-495. PubMed ID: 29253086
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mutations in the glucocerebrosidase gene and Parkinson's disease in Ashkenazi Jews.
    Aharon-Peretz J; Rosenbaum H; Gershoni-Baruch R
    N Engl J Med; 2004 Nov; 351(19):1972-7. PubMed ID: 15525722
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Serotonin and dopamine transporter PET changes in the premotor phase of LRRK2 parkinsonism: cross-sectional studies.
    Wile DJ; Agarwal PA; Schulzer M; Mak E; Dinelle K; Shahinfard E; Vafai N; Hasegawa K; Zhang J; McKenzie J; Neilson N; Strongosky A; Uitti RJ; Guttman M; Zabetian CP; Ding YS; Adam M; Aasly J; Wszolek ZK; Farrer M; Sossi V; Stoessl AJ
    Lancet Neurol; 2017 May; 16(5):351-359. PubMed ID: 28336296
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of elderly and young patient populations treated with deep brain stimulation for Parkinson's disease: long-term outcomes with up to 7 years of follow-up.
    Hanna JA; Scullen T; Kahn L; Mathkour M; Gouveia EE; Garces J; Evans LM; Lea G; Houghton DJ; Biro E; Bui CJ; Sulaiman OA; Smith RD
    J Neurosurg; 2018 Sep; 131(3):807-812. PubMed ID: 30265192
    [TBL] [Abstract][Full Text] [Related]  

  • 33. β-Glucocerebrosidase gene mutations in two cohorts of Greek patients with sporadic Parkinson's disease.
    Moraitou M; Hadjigeorgiou G; Monopolis I; Dardiotis E; Bozi M; Vassilatis D; Vilageliu L; Grinberg D; Xiromerisiou G; Stefanis L; Michelakakis H
    Mol Genet Metab; 2011; 104(1-2):149-52. PubMed ID: 21745757
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Autosomal dominant Parkinson's disease: Incidence of mutations in LRRK2, SNCA, VPS35 and GBA genes in Brazil.
    Abreu GM; Valença DC; Campos M; da Silva CP; Pereira JS; Araujo Leite MA; Rosso AL; Nicaretta DH; Vasconcellos LF; da Silva DJ; Della Coletta MV; Dos Santos JM; Gonçalves AP; Santos-Rebouças CB; Pimentel MM
    Neurosci Lett; 2016 Dec; 635():67-70. PubMed ID: 27777137
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Parkin mutation and deep brain stimulation outcome.
    Kim HJ; Yun JY; Kim YE; Lee JY; Kim HJ; Kim JY; Park SS; Paek SH; Jeon BS
    J Clin Neurosci; 2014 Jan; 21(1):107-10. PubMed ID: 24060625
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cancer outcomes among Parkinson's disease patients with leucine rich repeat kinase 2 mutations, idiopathic Parkinson's disease patients, and nonaffected controls.
    Agalliu I; Ortega RA; Luciano MS; Mirelman A; Pont-Sunyer C; Brockmann K; Vilas D; Tolosa E; Berg D; Warø B; Glickman A; Raymond D; Inzelberg R; Ruiz-Martinez J; Mondragon E; Friedman E; Hassin-Baer S; Alcalay RN; Mejia-Santana H; Aasly J; Foroud T; Marder K; Giladi N; Bressman S; Saunders-Pullman R
    Mov Disord; 2019 Sep; 34(9):1392-1398. PubMed ID: 31348549
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Advances in GBA-associated Parkinson's disease--Pathology, presentation and therapies.
    Barkhuizen M; Anderson DG; Grobler AF
    Neurochem Int; 2016 Feb; 93():6-25. PubMed ID: 26743617
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Serum lipid alterations in GBA-associated Parkinson's disease.
    Guedes LC; Chan RB; Gomes MA; Conceição VA; Machado RB; Soares T; Xu Y; Gaspar P; Carriço JA; Alcalay RN; Ferreira JJ; Outeiro TF; Miltenberger-Miltenyi G
    Parkinsonism Relat Disord; 2017 Nov; 44():58-65. PubMed ID: 28890071
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prevalence and clinical features of LRRK2 mutations in patients with Parkinson's disease in southern Spain.
    Gao L; Gómez-Garre P; Díaz-Corrales FJ; Carrillo F; Carballo M; Palomino A; Díaz-Martín J; Mejías R; Vime PJ; López-Barneo J; Mir P
    Eur J Neurol; 2009 Aug; 16(8):957-60. PubMed ID: 19473361
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Motor phenotype of LRRK2-associated Parkinson's disease: a Tunisian longitudinal study.
    Nabli F; Ben Sassi S; Amouri R; Duda JE; Farrer MJ; Hentati F
    Mov Disord; 2015 Feb; 30(2):253-8. PubMed ID: 25487881
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.